
Combining immune checkpoint blockade (ICB) with chemotherapy has shown improved outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. However, the efficacy of this combination in the perioperative setting was unknown. This phase 2 nonrandomized controlled trial aimed to evaluate the safety and preliminary activity of perioperative chemotherapy and ICB followed by maintenance ICB in resectable G/GEJ adenocarcinoma. Of the 34 evaluable patients, 20.6% achieved a pathologic complete response, and 17.6% achieved a pathologic near-complete response. Disease-free survival (DFS) and overall survival (OS) were encouraging, with 2-year rates of 67.8% and 80.6%, respectively. The treatment was well tolerated, with manageable adverse events. These results highlight the potential of checkpoint inhibition in combination with perioperative chemotherapy for locally advanced G/GEJ adenocarcinoma.
Like
Save
Share